First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.
Khalid Abd-ElazizChristine Voors-PetteKang-Ling WangSandy PanYisheng LeeJohn MaoYuhua LiBenjamin ChienDavid LauZuzana DiamantPublished in: Clinical drug investigation (2020)
www.clinicaltrials.gov : NCT02238834 (Study I); NCT03304964 (Study II). Trial registration date: Study I was registered on 12 September 2014 while study II was registered on 9 October 2017.